Educational information, not financial advice or a personal recommendation. Not regulated by the FCA. Do your own research. Capital at risk.
Sterling AlmanacExploreStart hereFind your fitGlossaryCompareMy ListMy PieEarnings calendarSupport

IDEXX Laboratories, Inc. (IDXX)

Healthcare High quality

IDEXX Laboratories is a global leader in pet healthcare, providing the diagnostic tests, software, and equipment that vets use to keep our furry friends healthy.

$559.07

Is IDEXX Laboratories, Inc. a good stock for a UK beginner?

The honest version: IDEXX Laboratories is a global leader in pet healthcare, providing the diagnostic tests, software, and equipment that vets use to keep our furry friends healthy.

No rating · no target price · nothing for sale here
Price+17.0%
Priced in USD - as a UK investor your £ return also moves with the pound-to-dollar exchange rate, on top of the share price itself.
52-week range+7% past year
$559.07
Low $518.55High $769.98
Where today's price sits versus its past year - context, not a signal.
If you had put $1,000 into IDEXX Laboratories, Inc.
$1,170+17%

Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.

Market cap: The company's total value on the stock market - share price times the number of shares. Big = 'large-cap', small = 'small-cap'.
$44.10B
Avg volume: How many shares change hands on a typical day. Higher means it's easy to buy or exit without moving the price.
644.70K
Day range: The lowest and highest price the shares traded at during the latest day.
$549.33 – $563.05
52-week range: The lowest and highest the shares have traded over the past year - a sense of how wide the swings have been.
$518.55 – $769.98
P/E ratio: Price-to-earnings: the share price divided by yearly profit per share. Lower can mean cheaper; higher often means investors expect fast growth.
41.1
Dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone.
0.0%
Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down.
1.55
How bumpy is it?Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down. 1.55
Calm
Wild
Bumpier than the market

Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.

Why has it been moving?▼ -1% past week · ▲ +7% past year

Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.

The bull case

IDEXX becomes the standard for all veterinary diagnostic software globally.

The bear case

A long-term shift in consumer spending away from premium pet health services.

What does IDEXX Laboratories, Inc. do?

IDEXX makes its money by selling the machines and lab services that help vets diagnose illnesses in pets quickly. Because pet owners are increasingly treating their animals like family members, the demand for high-quality medical care has been a steady engine for the company. The question that matters most is whether they can keep growing their diagnostic business as more pet owners seek advanced health insights for their companions.

VQGMI
Factor profile

On our factor screen it looks strongest on quality and growth, and weakest on value.

Value: How cheap the stock looks versus profits, sales and assets (higher = cheaper). 12Quality: How profitable and financially healthy the company is (higher = stronger). 75Growth: How fast revenue and earnings are growing (higher = faster). 58Momentum: How the share price has been trending recently (higher = stronger recent run). 26Income: The dividend income on offer and how sustainable it looks (higher = more/steadier). 16
Quick checks
What's strong
  • Quality screens high (75/100)
  • Strong profit margins showing a very efficient business model
  • High return on equity indicates excellent use of capital
  • Operates in a growing market as pet care becomes more advanced
What to watch
  • Value screens low (12/100)
  • Momentum screens low (26/100)
  • Income screens low (16/100)
  • Economic downturns could lead pet owners to cut back on non-essential vet visits
  • Reliance on the veterinary industry means it is vulnerable to changes in vet staffing or clinic profitability

What do IDEXX Laboratories, Inc.'s numbers mean?

P/E
41.5
This shows how much you are paying for every pound of the company's profit; a higher number suggests investors expect significant growth in the future.
Gross margin
62.1%
This tells us that for every pound of sales, the company keeps over 60 pence after paying for the direct costs of making its products.
Return on equity
72.9%
This is a measure of how efficiently the company uses the money shareholders have invested to generate profit, and this figure is exceptionally high.
Beta
1.5
This indicates the share price tends to be more jumpy or volatile than the wider stock market.

How much money does IDEXX Laboratories, Inc. make?

Revenue and profit by quarter, and how much of each sale turns into profit.

RevenueNet income
$0$285.20M$570.41M$855.62M$1.14BQ1 25Q2 25Q3 25Q4 25Q1 26
Gross margin
62.1%
Net margin
24.6%
Return on equity
72.9%

Does IDEXX Laboratories, Inc. pay a dividend?

No - IDEXX Laboratories, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.

More in Healthcare

Eli LillyWest Pharmaceutical Services, Inc.Incyte CorporationThe Cigna GroupZimmer Biomet Holdings, Inc.Moderna, Inc.Gilead Sciences, Inc.Regeneron Pharmaceuticals, Inc.
Appears in
Healthcare & pharma shares, explained

What are the scenarios for IDEXX Laboratories, Inc.?

An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.

$788$559$482today · $559▲ Bull · $601• Base · $559▼ Bear · $517in 1 yearILLUSTRATIVE · NOT A PREDICTION OR PRICE TARGET
Bull
+5% to +10%Stronger than expected demand for new diagnostic equipment.
Base
-2% to +2%Steady, predictable growth in line with historical trends.
Bear
-5% to -10%A slowdown in vet clinic visits due to tighter household budgets.

What are the pros and cons of IDEXX Laboratories, Inc.?

3bull points
6bear points

How many points the write-up makes each way — a balance check, not a score or verdict.

The bull case3
  • Strong profit margins showing a very efficient business model
  • High return on equity indicates excellent use of capital
  • Operates in a growing market as pet care becomes more advanced
The catch3
  • High valuation multiples suggest the shares are not cheap
  • Does not pay a dividend, so no regular cash income for investors
  • The share price can be quite volatile compared to the broader market
Key risks3
  • Economic downturns could lead pet owners to cut back on non-essential vet visits
  • Reliance on the veterinary industry means it is vulnerable to changes in vet staffing or clinic profitability
  • Technological disruption from new, lower-cost diagnostic competitors
What would flip the thesis

The write-up's own warning lights — if these start happening, the case above changes.

Confidence: medium · data: USD · flags: none · Charts by TradingView Lightweight Charts™
Found this useful? The Almanac is free and ad-free - a coffee keeps it that way.Support →

Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →

This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.

Figures as of 2026-08-01. Prices may be delayed and numbers can go stale - always double-check before acting.